The new classification of lung adenocarcinoma

Zentralblatt fur Chirurgie - Zeitschrift fur Allgemeine, Viszeral- und Gefasschirurgie

Volumn 138, Issue SUPPL 1, 2013, Pages

  Petersen, I ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

interdisciplinary; thoracic surgery; tumour growth

Indexed keywords

ADENOCARCINOMA; BIOPSY; CANCER GRADING; CARCINOMA IN SITU; CLASSIFICATION; COLLOID CARCINOMA; COOPERATION; HUMAN; INTERDISCIPLINARY COMMUNICATION; LUNG; LUNG ADENOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG TUMOR; MOLECULAR DIAGNOSIS; PATHOLOGY; PRECANCER; PROGNOSIS; REVIEW; TUMOR INVASION;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADENOCARCINOMA, MUCINOUS; ADENOMATOSIS, PULMONARY; BIOPSY; CARCINOMA IN SITU; COOPERATIVE BEHAVIOR; HUMANS; INTERDISCIPLINARY COMMUNICATION; LUNG; LUNG NEOPLASMS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PRECANCEROUS CONDITIONS; PROGNOSIS;

EID: 84887489767     PISSN: 0044409X     EISSN: 14389592     Source Type: Journal    
DOI: 10.1055/s-0033-1350878     Document Type: Article

References (57)

1. Travis W. D., Brambilla E., Noguchi M. et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol: 2011; 6 244 285
2. Petersen I. [Morphological and molecular pathology of lung cancer]. Pathologe: 2010; 31 02 S204 S210
3. Petersen I. The morphological and molecular diagnosis of lung cancer. Dtsch Arztebl Int: 2011; 108 525 531
4. Warth A., Muley T., Meister M. et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol: 2012; 30 1438 1446
5. Warth A., Cortis J., Fink L. et al. Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification. Virchows Arch: 2012; 461 185 193
6. Warth A., Stenzinger A., von Brünneck A. C. et al. Interobserver variability in the application of the novel IASLC/ATS/ERS classification for pulmonary adenocarcinomas. Eur Respir J: 2012; 40 1221 1227
7. Schnabel P. A., Petersen I., Junker K. [Current issues in pulmonary pathology. Report of the working group on pulmonary pathology of the German Society of Pathology]. Pathologe: 2012; 33 02 S351 S354
8. Mireskandari M., Abdirad A., Zhang Q. et al. Association of small foci of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) with adenocarcinoma of the lung. Pathol Res Pract: 2013; 10.1016/j.prp.2013.06.019
9. Petersen I., Schnabel P. A. [Whats new in lung pathology: minutes from the Pulmonary Pathology Working Group of the German Society of Pathology]. Pathologe: 2011; 32 02 351 357
10. Warth A., Herpel E., Schmähl A. et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) in association with an adenocarcinoma: a case report. J Med Case Rep: 2008; 2 21
11. Jones K. D. Whence Lepidic? Arch Pathol Lab Med: 2013; [Epub ahead of print]
12. Thunnissen E., Beasley M. B., Borczuk A. C. et al. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol: 2012; 25 1574 1583
13. Miyoshi T., Satoh Y., Okumura S. et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol: 2003; 27 101 109
14. Yoshida A., Tsuta K., Watanabe S. et al. Frequent ALK rearrangement and TTF-1/p 63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer: 2011; 72 309 315
15. Popat S., Gonzalez D., Min T. et al. ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma. Lung Cancer: 2012; 75 300 305
16. Sica G., Yoshizawa A., Sima C. S. et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol: 2010; 34 1155 1162
17. Russell P. A., Wainer Z., Wright G. M. et al. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol: 2011; 6 1496 1504
18. Yoshizawa A., Motoi N., Riely G. J. et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol: 2011; 24 653 664
19. Shim H. S., Lee da H., Park E. J. et al. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. Arch Pathol Lab Med: 2011; 135 1329 1334
20. Solis L. M., Behrens C., Raso M. G. et al. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer: 2012; 118 2889 2899
21. Sterlacci W., Savic S., Schmid T. et al. Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact. Am J Clin Pathol: 2012; 137 946 956
22. Yeh Y. C., Wu Y. C., Chen C. Y. et al. Stromal invasion and micropapillary pattern in 212 consecutive surgically resected stage I lung adenocarcinomas: histopathological categories for prognosis prediction. J Clin Pathol: 2012; 65 910 918
23. Russell P. A., Barnett S. A., Walkiewicz M. et al. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. J Thorac Oncol: 2013; 8 461 468
24. Gu J., Lu C., Guo J. et al. Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients-A single institution retrospective study of 292 lung adenocarcinoma. J Surg Oncol: 2013; 107 474 480
25. Yoshizawa A., Sumiyoshi S., Sonobe M. et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol: 2013; 8 52 61
26. Petersen I., Kotb W. F., Friedrich K. H. et al. Core classification of lung cancer: correlating nuclear size and mitoses with ploidy and clinicopathological parameters. Lung Cancer: 2009; 65 312 318
27. Kotb W. F., Petersen I. Morphology, DNA ploidy and HPV in lung cancer and head and neck cancer. Pathol Res Pract: 2012; 208 1 8
28. Schulze S., Petersen I. Gender and ploidy in cancer survival. Cell Oncol (Dordr): 2011; 34 199 208
29. Nakazato Y., Minami Y., Kobayashi H. et al. Nuclear grading of primary pulmonary adenocarcinomas: correlation between nuclear size and prognosis. Cancer: 2010; 116 2011 2019
30. Nakazato Y., Maeshima A. M., Ishikawa Y. et al. Interobserver agreement in the nuclear grading of primary pulmonary adenocarcinoma. J Thorac Oncol: 2013; 8 736 743
31. Kadota K., Suzuki K., Kachala S. S. et al. A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol: 2012; 25 1117 1127
32. Weihmann J., Weichert C., Petersen I. et al. [Evaluation of a cell block method in cytological diagnostics]. Pathologe: 2012; 33 553 559
33. Warth A., Bubendorf L., Gütz S. et al. [Molecular pathological diagnosis in cytopathology of non-small-cell lung cancer: Standardization of specimen processing]. Pathologe: 2013; 34 310 317
34. Herth F. J., Bubendorf L., Gütz S. et al. [Diagnostic and predictive analyses of cytological specimens of non-small cell lung cancer: strategies and challenges]. Pneumologie: 2013; 67 198 204
35. Kayser G., Csanadi A., Otto C. et al. Simultaneous multi-antibody staining in non-small cell lung cancer strengthens diagnostic accuracy especially in small tissue samples. PLoS One: 2013; 8 e56333
36. Lindeman N. I., Cagle P. T., Beasley M. B. et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med: 2013; 137 828 860
37. Thunnissen E., Bubendorf L., Dietel M. et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch: 2012; 461 245 257
38. Thunnissen E., Kerr K. M., Herth F. J. et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer: 2012; 76 1 18
39. Warth A., Stenzinger A., Weichert W. [Novel morphological and molecular aspects of lung cancer]. Pathologe: 2013; 34 419 428
40. Travis W. D., Brambilla E., Noguchi M. et al. Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med: 2013; 137 685 705
41. Lederlin M., Puderbach M., Muley T. et al. Correlation of radio- and histomorphological pattern of pulmonary adenocarcinoma. Eur Respir J: 2013; 41 943 951
42. Goeckenjan G., Sitter H., Thomas M. et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer]. Pneumologie: 2010; 64 02 e1 e164
43. Petersen I. Morphologische Analyse und molekulare Diagnostik. Schwerpunkt: Lungenkarzinom. ONKOLOGIE heute: 2012; 3 11 13
44. Takeuchi K., Soda M., Togashi Y. et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med: 2012; 18 378 381
45. Cardarella S., Johnson B. E. The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med: 2013; Jul 10 [Epub ahead of print]
46. Nitsche K., Günther B., Katenkamp D. et al. Thoracic neoplasms at the Jena reference center for soft tissue tumors. J Cancer Res Clin Oncol: 2012; 138 415 424
47. Jakobsen J. N., Sorensen J. B. Clinical impact of ki-67 labeling index in non-small cell lung cancer. Lung Cancer: 2013; 79 1 7
48. Kadota K., Nitadori J., Sarkaria I. S. et al. Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma. Cancer: 2013; 119 931 938
49. Ordóñez N. G. Napsin A expression in lung and kidney neoplasia: a review and update. Adv Anat Pathol: 2012; 19 66 73
50. Penzel R., Sers C., Chen Y. et al. EGFR mutation detection in NSCLC-assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. Virchows Arch: 2011; 458 95 98
51. von Laffert M., Warth A., Penzel R. et al. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): Results of a multi-centre ALK-testing. Lung Cancer: 2013; 81 200 206
52. Imielinski M., Berger A. H., Hammerman P. S. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell: 2012; 150 1107 1120
53. Hanahan D., Weinberg R. A. Hallmarks of cancer: the next generation. Cell: 2011; 144 646 674
54. Yang L., Chen Y., Cui T. et al. Desmoplakin acts as a tumor suppressor by inhibition of the Wnt/β-catenin signaling pathway in human lung cancer. Carcinogenesis: 2012; 33 1863 1870
55. Cui T., Chen Y., Yang L. et al. The p 53 target gene desmocollin 3 acts as a novel tumor suppressor through inhibiting EGFR/ERK pathway in human lung cancer. Carcinogenesis: 2012; 33 2326 2333
56. Soda M., Takada S., Takeuchi K. et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A: 2008; 105 19893 19897
57. Arai Y., Totoki Y., Takahashi H. et al. Mouse model for ROS1-rearranged lung cancer. PLoS One: 2013; 8 e56010